<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650608</url>
  </required_header>
  <id_info>
    <org_study_id>HL217-101</org_study_id>
    <nct_id>NCT03650608</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo Controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics After Single Dosing of HL217 Eye Drop in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and PK parameters in
      healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and PK parameters of HL217
      after single eye drop administration at different doses in healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical parameter: Adverse Events (AE)</measure>
    <time_frame>During 72hours</time_frame>
    <description>AEs will be coded according to the MedDRA. They will be classified into pre-defined standard categories according to chronological criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tolerance: Redness, Tingling and Other ophthalmic adverse events</measure>
    <time_frame>During 72hours</time_frame>
    <description>Redness, tingling and others should be checked</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment: Cmax</measure>
    <time_frame>0hour (Pre-dose), 0.25hour, 0.5hour, 0.75hour, 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 11hour, 12hour, 24hour, 72hour</time_frame>
    <description>observed maximum plasma concentration of HL217</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment: Tmax</measure>
    <time_frame>0hour (Pre-dose), 0.25hour, 0.5hour, 0.75hour, 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 11hour, 12hour, 24hour, 72hour</time_frame>
    <description>first time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment: AUClast</measure>
    <time_frame>0hour (Pre-dose), 0.25hour, 0.5hour, 0.75hour, 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 11hour, 12hour, 24hour, 72hour</time_frame>
    <description>area under the plasma concentration curve from administration up to the last quantifiable concentration at time 72h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment: AUCinf</measure>
    <time_frame>0hour (Pre-dose), 0.25hour, 0.5hour, 0.75hour, 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 11hour, 12hour, 24hour, 72hour</time_frame>
    <description>area under the plasma concentration-time curve from administration up to infinity with extrapolation of the terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment: Kel</measure>
    <time_frame>0hour (Pre-dose), 0.25hour, 0.5hour, 0.75hour, 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 11hour, 12hour, 24hour, 72hour</time_frame>
    <description>elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment: T1/2</measure>
    <time_frame>0hour (Pre-dose), 0.25hour, 0.5hour, 0.75hour, 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 11hour, 12hour, 24hour, 72hour</time_frame>
    <description>plasma elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment: %AUCextra</measure>
    <time_frame>0hour (Pre-dose), 0.25hour, 0.5hour, 0.75hour, 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 11hour, 12hour, 24hour, 72hour</time_frame>
    <description>percentage of extrapolated AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment: Cl/F</measure>
    <time_frame>0hour (Pre-dose), 0.25hour, 0.5hour, 0.75hour, 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 11hour, 12hour, 24hour, 72hour</time_frame>
    <description>clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment: Vd/F</measure>
    <time_frame>0hour (Pre-dose), 0.25hour, 0.5hour, 0.75hour, 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 11hour, 12hour, 24hour, 72hour</time_frame>
    <description>volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>Cohort 1: HL217 Ophathalmic Solution QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL217 3mg/mL, Ophthalmic solution, two drop once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: HL217 Ophathalmic Solution BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL217 3mg/mL, Ophthalmic solution, two drop twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: HL217 Ophthalmic Solution QID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL217 3mg/mL, Ophthalmic solution, two drop four times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Ophthalmic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Ophthalmic solution, two drop once or twice or four times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1: HL217 Ophathalmic Solution QD</intervention_name>
    <description>Cohort 1 (Once a day)</description>
    <arm_group_label>Cohort 1: HL217 Ophathalmic Solution QD</arm_group_label>
    <other_name>3mg/mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2: HL217 Ophathalmic Solution BID</intervention_name>
    <description>Cohort 2 (Twice a day)</description>
    <arm_group_label>Cohort 2: HL217 Ophathalmic Solution BID</arm_group_label>
    <other_name>3mg/mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 3: HL217 Ophthalmic Solution QID</intervention_name>
    <description>Cohort 3 (Four times a day)</description>
    <arm_group_label>Cohort 3: HL217 Ophthalmic Solution QID</arm_group_label>
    <other_name>3mg/mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ophthalmic solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Ophthalmic solution</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subject, aged between 18 and 50 years inclusive

          2. Non-smoker subject or smoker of not more than 10 cigarettes a day and able to stop
             smoking 24 hour prior to admission until discharge

          3. Body weight ≥ 50 kg and BMI between 18 and 30 kg/m²

          4. Certified as healthy by a comprehensive clinical assessment (detailed medical history
             and complete physical examination) including complete ocular examination

          5. Normal Blood Pressure (BP) and Heart Rate (HR) after 10 minutes in supine position:

               -  90 mmHg ≤ Systolic Blood Pressure (SBP) ≤ 140 mmHg

               -  45 mmHg ≤ Diastolic Blood Pressure (DBP) ≤ 90 mmHg

               -  40 bpm ≤ HR ≤ 100 bpm

               -  Or considered NCS by investigators

          6. Normal ECG recording on a 12-lead ECG:

               -  120 &lt; PR &lt; 200 ms

               -  QRS &lt; 120 ms

               -  QTcf ≤ 430 ms

               -  No sign of any trouble of sinusal automatism

               -  Or considered NCS by investigators

          7. Laboratory parameters within the normal range of the laboratory (haematological, blood
             chemistry tests, urinalysis). Individual values out of the normal range can be
             accepted if judged clinically non relevant by the Investigator

          8. Normal dietary habits

          9. Signing a written informed consent prior to selection

        Exclusion Criteria:

          1. Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic,
             renal, metabolic, haematological, neurologic, psychiatric, systemic, infectious or
             ocular disease

          2. Frequent headaches and / or migraine, recurrent nausea and / or vomiting

          3. Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic
             postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20
             mmHg within two minutes when changing from the supine to the standing position

          4. Blood donation (including in the frame of a clinical trial) within 2 months before
             administration or apheresis within 20 days before administration

          5. General anaesthesia within 3 months before administration

          6. Presence or history of drug hypersensitivity, or allergic disease diagnosed and
             treated by a physician (including allergy to fluorescein)

          7. Inability to abstain from intensive muscular effort

          8. No next of kin, easily accessible, in case of emergency

          9. Any drug or herbal medicine intake (except paracetamol) during the last 14 days prior
             to the first administration, any over the counter medicine or vitamin during the last
             7 days prior to the first administration

         10. Subjects who have taken drug metabolizing enzyme inducing agents and inhibitors such
             as barbitals within a month prior to the first administration

         11. History or presence of drug or alcohol abuse (alcohol consumption &gt; &gt;21 units per
             week)

         12. Excessive consumption of beverages with xanthine bases (&gt; 5 cups or glasses / day) and
             not able to stop 24h prior to admission until discharge

         13. Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody,
             or positive results for Human Immunodeficiency Virus (HIV) 1 or 2

         14. Major surgery (general or ocular) within 28 days prior to randomization or major
             surgery planned during the next 6 months

         15. Subject who, in the judgment of the Investigator, is likely to be non-compliant or
             uncooperative during the study, or unable to cooperate because of a language problem,
             poor mental development

         16. Subjects within an exclusion period of a previous study or subjects who have taken any
             investigational product from other clinical trials within 60 days from the start of
             the study (from the administration of investigational product)

         17. Subjects with previous participation in the current study

         18. Subject under administrative or legal supervision

         19. Subjects with an allergy to Fluorescein

         20. History of any ocular surgery within the past 6 months prior to study participation

         21. Subject who have intraocular pressure &gt; 21 mmHg

         22. Subject with acute or chronic eye problems that require eye drop at the time of
             screening

         23. Best-corrected ETDRS visual acuity score ≤ 85 (Snellen equivalent 20/20)

         24. Subject who need to wear contact lens during the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bell</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioKinetic Europe</affiliation>
  </overall_official>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

